SCHEMBL1917819

SCHEMBL1917819

Cc1nc2c(s1)C(=O)C=C(NCCN(C)C)C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 1.00
CDC25B P30305 2/20 1.00
CDC25C P30307 2/20 1.00
CDK4 P11802 9/20 0.55
MEN1 O00255 1/20 0.55
THRB P10828 1/20 0.55
CCND1 P24385 1/20 0.55
BLM P54132 1/20 0.55
KMT2A Q03164 1/20 0.55
KMT5A Q9NQR1 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MALT1 Q9UDY8 1/20 0.49
HSD17B10 Q99714 1/20 0.39
ATAD2 Q6PL18 2/20 0.38
HRH3 Q9Y5N1 1/20 0.34
BRD4 O60885 1/20 0.34
S100A4 P26447 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4209583 0.99 CDC25A (0.97) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL1917822 0.92 CDC25A (0.85) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL2401631 0.92 CDC25A (0.85) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL1917956 0.91 CDC25A (0.83) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL1918954 0.90 CDC25A (0.81) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL1918019 0.90 CDC25A (0.81) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL1919295 0.88 CDC25A (0.79) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL2398380 0.87 CDC25A (0.77) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL3813511 0.87 CDC25A (0.77) CDC25ACDC25BCDC25CCDK4MEN1
SCHEMBL3809294 0.86 CDC25A (0.76) CDC25ACDC25BCDC25CCDK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253685-A1 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES 2009-10-08 US claimed
EP-1641453-B1 PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT IPSEN PHARMA (FR) 2009-08-19 EP claimed
US-20090082345-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-03-26 US claimed
US-7495021-B2 Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 US claimed
US-20070255063-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-11-01 US claimed
US-7279467-B2 Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-10-09 US claimed
EP-1461326-B1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOD CONSEILS RECH APPLIC (FR) 2007-08-01 EP claimed
US-20060281736-A1 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2006-12-14 US claimed
EP-1641453-A2 PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-04-05 EP claimed
WO-2005000852-A2 PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2005-01-06 WO claimed
JP-2004533456-A 2004-11-04 JP claimed
EP-1461326-A1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-09-29 EP claimed
EP-1438039-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-21 EP claimed
US-20040138245-A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-15 US claimed
WO-2003055868-A1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2003-07-10 WO claimed
WO-2002096348-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-12-05 WO claimed
US-20240110230-A1 BIOMARKERS FOR CANCER TREATMENT FOUNDATION MEDICINE, INC. (US) 2024-04-04 US disclosed
EP-4291902-A2 BIOMARKERS FOR CANCER TREATMENT Foundation Medicine, Inc. (US) 2023-12-20 EP disclosed
WO-2003055868-A1 BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2003-07-10 WO disclosed
WO-2002096348-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138245-A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment DTYMK, DGKG, DGKZ CDC25A 261/4885CDC25B 306/4885CDC25C 186/4885
US-20060281736-A1 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent CDC25A, CDC25C, CDC25B CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885
US-20070255063-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS CDC25A, CDC25C, CDC25B CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885
US-20090253685-A1 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent CDC25A, CDC25C, CDC25B CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885
US-20090082345-A1 BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.